.Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J02A_AntimycoticsForSystemicUse.J02AC05_Isavuconazole.Isavuconazole .Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J02A_AntimycoticsForSystemicUse.J02AC05_Isavuconazole.Isavuconazole| name: | Isavuconazole |
| ATC code: | J02AC05 | route: | oral |
| n-compartments | 2 |
Isavuconazole is a triazole antifungal medication approved for the treatment of invasive aspergillosis and mucormycosis. It is used in adults and is active against a broad spectrum of pathogenic fungi. Isavuconazole is approved for clinical use in several countries, including the US and EU.
Pharmacokinetic parameters reported for healthy adult subjects following oral administration of isavuconazole (as the prodrug isavuconazonium sulfate).
Chen, N, et al., & Lu, X (2023). Population Pharmacokinetics of Isavuconazole in Adult: A Systematic Review. Infection and drug resistance 16 7559–7568. DOI:10.2147/IDR.S434622 PUBMED:https://pubmed.ncbi.nlm.nih.gov/38089964
Zhou, J, et al., & Wu, X (2024). Optimization of oral isavuconazole dose for population in special physiological or pathological state: a physiologically based pharmacokinetics model-informed precision dosing. The Journal of antimicrobial chemotherapy 79(9) 2379–2389. DOI:10.1093/jac/dkae240 PUBMED:https://pubmed.ncbi.nlm.nih.gov/39086118
Arrieta, AC, et al., & Walsh, TJ (2021). Safety, Tolerability, and Population Pharmacokinetics of Intravenous and Oral Isavuconazonium Sulfate in Pediatric Patients. Antimicrobial agents and chemotherapy 65(8) e0029021–None. DOI:10.1128/AAC.00290-21 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34031051